Apex is a Phase 2 clinical trial evaluating bezuclastinib (CGT9486), a selective and potent KIT inhibitor, in people with Advanced Systemic Mastocytosis (AdvSM).LEARN MORE
Summit is a Phase 2 clinical trial evaluating bezuclastinib (CGT9486), a selective and potent KIT inhibitor, in people with Nonadvanced Systemic Mastocytosis (NonAdvSM).LEARN MORE
Peak is a Phase 3 clinical trial evaluating bezuclastinib (CGT9486), a selective and potent KIT inhibitor, in combination with sunitinib vs. sunitinib alone, in people with Gastrointestinal Stromal Tumors (GIST).LEARN MORE
Below are some frequently asked questions about the clinical trials:
Before any treatment, such as a drug, can be recommended for use, it must be evaluated in a clinical trial. This regulated research study evaluates its safety and efficacy in human volunteers. Your rights and safety are top priorities when researchers design a clinical trial. Ethical approval by regulatory agencies and informed consent documents are in place for your protection.
By enrolling in research studies, you are taking an active role in your own care and the pursuit of better treatments for your disease.
Every clinical trial has different eligibility criteria that must be met for a person to be included. These criteria include age, type or stage of disease, medical history, use of other medications, and the ability to perform certain activities. Enrolling participants with similar characteristics ensures the results reflect what is being studied, not other factors. Eligibility criteria help researchers achieve accurate and meaningful results.
Yes, your participation in this clinical trial is entirely voluntary.
There may be a cost to you that includes basic expenses, co-pays, and/or deductibles as required by your insurance for routine standard medical care. However, study drug and clinical trial-related services and procedures that are not part of routine standard medical care will be provided to you at no charge.
Please go to www.clinicaltrials.gov.
Cogent Biosciences, Inc. is a biotechnology company developing real solutions to treat genetically driven diseases. With a focus on the design of rational precision therapies, we are leveraging validated biology to address the true underlying drivers of disease and provide real hope for patients.
Millions of people around the world are living with a genetically defined disease. Genetically defined diseases are diseases in which specific genetic mutations are known to cause disease, and can create a ripple effect in the body to trigger illness – cancers, autoimmune conditions, and rare diseases. For most of these diseases, despite the available therapies, there still exists a significant unmet need to extend survival and improve the quality of life for patients.
Please explore our website to find out more.